Key Points
-
Primary hyperparathyroidism (PHPT), a common endocrine disorder characterized by hypercalcaemia and elevated or inappropriately normal levels of parathyroid hormone, is diagnosed based upon biochemical evaluation
-
Over the past 50 years, the clinical profile of PHPT has evolved from a highly symptomatic disease to one that is most often asymptomatic, albeit with evidence of subclinical target organ involvement
-
Even 'asymptomatic' patients can have skeletal deterioration (evident upon imaging; for example, dual-energy X-ray absorptiometry), and subclinical manifestations can include osteoporosis and hypercalciuria as well as clinically silent vertebral fractures and nephrolithiasis
-
The diagnosis of normocalcaemic PHPT can be made after eliminating secondary causes of hyperparathyroidism; however, data are limited on its natural history and appropriate criteria for and response to surgery
-
Parathyroidectomy by an experienced parathyroid surgeon is recommended for patients with symptomatic disease or subclinical end-organ involvement, as no single medical therapy addresses hypercalcaemia and the skeletal and renal consequences of PHPT
Abstract
In this Review, we describe the pathogenesis, diagnosis and management of primary hyperparathyroidism (PHPT), with a focus on recent advances in the field. PHPT is a common endocrine disorder that is characterized by hypercalcaemia and elevated or inappropriately normal serum levels of parathyroid hormone. Most often, the presentation of PHPT is asymptomatic in regions of the world where serum levels of calcium are routinely measured. In addition to mild hypercalcaemia, PHPT can manifest with osteoporosis and hypercalciuria as well as with vertebral fractures and nephrolithiasis, both of which can be asymptomatic. Other clinical forms of PHPT, such as classical disease and normocalcaemic PHPT, are less common. Parathyroidectomy, the only curative treatment for PHPT, is recommended in patients with symptoms and those with asymptomatic disease who are at risk of progression or have subclinical evidence of end-organ sequelae. Parathyroidectomy results in an increase in BMD and a reduction in nephrolithiasis. Various medical therapies can increase BMD or reduce serum levels of calcium, but no single drug can do both. More data are needed regarding the neuropsychological manifestations of PHPT and the pathogenetic mechanisms leading to sporadic PHPT, as well as on risk factors for complications of the disorder. Future work that advances our knowledge in these areas will improve the management of the disorder.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cope, O. The study of hyperparathyroidism at the Massachusetts General Hospital. N. Engl. J. Med. 274, 1174–1182 (1966).
Yeh, M. W. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J. Clin. Endocrinol. Metab. 98, 1122–1129 (2013).
Wermers, R. A. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J. Bone Miner. Res. 21, 171–177 (2006).
Press, D. M. et al. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery 154, 1232–1237 (2013).
Heath, H. 3rd, Hodgson, S. F. & Kennedy, M. A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N. Engl. J. Med. 302, 189–193 (1980).
Wermers, R. A. et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965–1992. Ann. Intern. Med. 126, 433–440 (1997).
Griebeler, M. L. et al. Secular trends in the incidence of primary hyperparathyroidism over five decades. Bone 73, 1–7 (2015).
Silverberg, S. J., Shane, E., Jacobs, T. P., Siris, E. & Bilezikian, J. P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341, 1249–1255 (1999).
Rao, S. D. et al. Hyperparathyroidism following head and neck irradiation. Arch. Intern. Med. 140, 205–207 (1980).
Bendz, H., Sjodin, I., Toss, G. & Berglund, K. Hyperparathyroidism and long-term lithium therapy — a cross-sectional study and the effect of lithium withdrawal. J. Intern. Med. 240, 357–365 (1996).
Newey, P. J. et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J. Clin. Endocrinol. Metab. 97, E1995–E2005 (2012).
Costa-Guda, J. & Arnold, A. Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors. Mol. Cell. Endocrinol. 386, 46–54 (2014).
Pardi, E. et al. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 98, 2800–2810 (2013).
Arnold, A. M. & Levine, M. A. in The Parathyroids: Basic and Clinical Concepts (ed. Bilezikian, J. P.) 279–297 (Academic Press, 2015).
Marx, S. J. et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J. Bone Miner. Res. 17 (Suppl. 2), N37–N43 (2002).
Thakker, R. V. Genetics of parathyroid tumours. J. Intern. Med. 280, 574–583 (2016).
Guan, B. et al. GCM2-activating mutations in familial isolated hyperparathyroidism. Am. J. Hum. Genet. 99, 1034–1044 (2016).
Yu, W. et al. Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J. Clin. Endocrinol. Metab. 100, E360–E364 (2015).
Corbetta, S. et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr. Relat. Cancer 17, 135–146 (2010).
Brown, E. M. Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 27, 333–343 (2013).
Mahoney, E. J., Monchik, J. M., Donatini, G. & De Lellis, R. Life-threatening hypercalcemia from a hepatocellular carcinoma secreting intact parathyroid hormone: localization by sestamibi single-photon emission computed tomographic imaging. Endocr. Pract. 12, 302–306 (2006).
Nussbaum, S. R., Gaz, R. D. & Arnold, A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N. Engl. J. Med. 323, 1324–1328 (1990).
D'Amour, P. et al. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1–84) is overproduced in primary and secondary hyperparathyroidism. Clin. Chem. 49, 2037–2044 (2003).
Eastell, R. et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3570–3579 (2014).
Wilhelm, S. M. et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 151, 959–968 (2016).
Eastell, R. et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94, 340–350 (2009).
Nesbit, M. A. et al. Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368, 2476–2486 (2013).
Nesbit, M. A. et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat. Genet. 45, 93–97 (2013).
Lowe, H., McMahon, D. J., Rubin, M. R., Bilezikian, J. P. & Silverberg, S. J. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007).
Albright, F., Aub, J. & Bauer, W. Hyperparathyroidism: common and polymorphic condition as illustrated by seventeen proven cases in one clinic. JAMA 102, 1276 (1934).
Silverberg, S. J. et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3580–3594 (2014).
Usta, A., Alhan, E., Cinel, A., Turkyilmaz, S. & Erem, C. A 20-year study on 190 patients with primary hyperparathyroidism in a developing country: Turkey experience. Int. Surg. 100, 648–655 (2015).
Mallette, L. E., Bilezikian, J. P., Heath, D. A. & Aurbach, G. D. Primary hyperparathyroidism: clinical and biochemical features. Med. (Baltimore) 53, 127–146 (1974).
Liu, J. M. et al. Primary hyperparathyroidism: a tale of two cities revisited — New York and Shanghai. Bone Res. 1, 162–169 (2013).
Malabu, U. H. & Founda, M. A. Primary hyperparathyroidism in Saudi Arabia: a review of 46 cases. Med. J. Malaysia 62, 394–397 (2007).
Paruk, I. M., Esterhuizen, T. M., Maharaj, S., Pirie, F. J. & Motala, A. A. Characteristics, management and outcome of primary hyperparathyroidism in South Africa: a single-centre experience. Postgrad. Med. J. 89, 626–631 (2013).
Shah, V. N., Bhadada, S., Bhansali, A., Behera, A. & Mittal, B. R. Changes in clinical and biochemical presentations of primary hyperparathyroidism in India over a period of 20 years. Indian J. Med. Res. 139, 694–699 (2014).
Zhao, L. et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J. Clin. Endocrinol. Metab. 98, 721–728 (2013).
Bandeira, F. & Cassibba, S. Hyperparathyroidism and bone health. Curr. Rheumatol. Rep. 17, 48 (2015).
Oliveira, U. E. et al. Analysis of the diagnostic presentation profile, parathyroidectomy indication and bone mineral density follow-up of Brazilian patients with primary hyperparathyroidism. Braz. J. Med. Biol. Res. 40, 519–526 (2007).
Spivacow, F. R., Martinez, C. & Polonsky, A. [Primary hyperparathyroidism: postoperative long-term evolution]. Medicina (B. Aires) 70, 408–414 (in Spanish) (2010).
Walker, M. D. et al. Low vitamin D levels have become less common in primary hyperparathyroidism. Osteoporos. Int. 26, 2837–2843 (2015).
Moosgaard, B. et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 63, 506–513 (2005).
Boudou, P., Ibrahim, F., Cormier, C., Sarfati, E. & Souberbielle, J. C. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J. Endocrinol. Invest. 29, 511–515 (2006).
Clements, M. R. et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin. Endocrinol. (Oxf.) 37, 17–27 (1992).
Clements, M. R. et al. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin. Sci. (Lond.) 73, 659–664 (1987).
Rao, D. S. et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J. Clin. Endocrinol. Metab. 85, 1054–1058 (2000).
Silverberg, S. J., Shane, E., Dempster, D. W. & Bilezikian, J. P. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am. J. Med. 107, 561–567 (1999).
Tassone, F. et al. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin. Endocrinol. (Oxf.) 79, 784–790 (2013).
Viccica, G., Cetani, F., Vignali, E., Miccoli, M. & Marcocci, C. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine 55, 256–265 (2017).
Walker, M. D. et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J. Clin. Endocrinol. Metab. 100, 3443–3451 (2015).
Yamashita, H. et al. Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J. Surg. 26, 937–941 (2002).
Ozbey, N. et al. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J. Surg. 30, 321–326 (2006).
Jayasena, C. N. et al. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 78, 838–843 (2013).
Inoue, Y. et al. Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr. J. 55, 57–65 (2008).
Moosgaard, B. et al. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol. 155, 237–244 (2006).
Moosgaard, B. et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 68, 707–715 (2008).
Shah, V. N., Shah, C. S., Bhadada, S. K. & Rao, D. S. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin. Endocrinol. (Oxf.) 80, 797–803 (2014).
Rolighed, L. et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 99, 1072–1080 (2014).
Silverberg, S. J. et al. Skeletal disease in primary hyper- parathyroidism. J. Bone Miner. Res. 4, 283–291 (1989).
Parisien, M. et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J. Clin. Endocrinol. Metab. 70, 930–938 (1990).
Cipriani, C. et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J. Clin. Endocrinol. Metab. 100, 13091315 (2015).
Khosla, S. et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J. Bone Miner. Res. 14, 1700–1707 (1999).
Vignali, E. et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2306–2312 (2009).
Mosekilde, L. Primary hyperparathyroidism and the skeleton. Clin. Endocrinol. (Oxf.) 69, 1–19 (2008).
De Geronimo, S., Romagnoli, E., Diacinti, D., D'Erasmo, E. & Minisola, S. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur. J. Endocrinol. 155, 415–420 (2006).
Stein, E. M. et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J. Bone Miner. Res. 28, 1029–1040 (2013).
Walker, M. D. et al. Effect of concomitant vitamin D deficiency or insufficiency on lumbar spine volumetric bone mineral density and trabecular bone score in primary hyperparathyroidism. Osteoporos. Int. 27, 3063–3071 (2016).
Hansen, S., Hauge, E. M., Rasmussen, L., Jensen, J. E. & Brixen, K. Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism. A 1-year prospective controlled study using high resolution peripheral quantitative computed tomography. J. Bone Miner. Res. 27, 1150–1158 (2012).
Nordenstrom, E., Westerdahl, J., Lindergard, B., Lindblom, P. & Bergenfelz, A. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J. Surg. 26, 1463–1467 (2002).
Bilezikian, J. P. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014).
Lundstam, K. et al. Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 100, 1359–1367 (2015).
Rejnmark, L., Vestergaard, P. & Mosekilde, L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 96, 2377–2385 (2011).
Cassibba, S. et al. Silent renal stones in primary hyperparathyroidism: prevalence and clinical features. Endocr. Pract. 20, 1137–1142 (2014).
Odvina, C. V. et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol. Res. 35, 123–128 (2007).
Berger, A. D. et al. Patients with primary hyperparathyroidism — why do some form stones? J. Urol. 181, 2141–2145 (2009).
Tassone, F., Gianotti, L., Emmolo, I., Ghio, M. & Borretta, G. Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 4458–4461 (2009).
Walker, M. D. et al. Predictors of renal function in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 99, 1885–1892 (2014).
Walker, M. D. et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 97, 1501–1507 (2012).
Rao, D. S., Wilson, R. J., Kleerekoper, M. & Parfitt, A. M. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J. Clin. Endocrinol. Metab. 67, 1294–1298 (1988).
Kristoffersson, A., Backman, C., Granqvist, K. & Jarhult, J. Pre- and postoperative evaluation of renal function with five different tests in patients with primary hyperparathyroidism. J. Intern. Med. 227, 317–324 (1990).
Ambrogini, E. et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J. Clin. Endocrinol. Metab. 92, 3114–3121 (2007).
Bollerslev, J. et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 92, 1687–1692 (2007).
Ogino, K., Burkhoff, D. & Bilezikian, J. P. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 136, 3024–3030 (1995).
Collip, J. B. & Clark, E. P. Further studies on the physiological action of a parathyroid hormone. J. Biol. Chem. 64, 4485–507 (1925).
Walker, M. D. et al. Carotid vascular abnormalities in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 3849–3856 (2009).
Walker, M. D. & Silverberg, S. J. Parathyroidectomy in asymptomatic primary hyperparathyroidism: improves “bones” but not “psychic moans”. J. Clin. Endocrinol. Metab. 92, 1613–1615 (2007).
Talpos, G. B. et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 128, 1013–1020 (2000).
Perrier, N. D. et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery 146, 1116–1122 (2009).
Walker, M. D. & Silverberg, S. J. Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925–931 (2008).
Soreide, J. A. et al. Survival after surgical treatment for primary hyperparathyroidism. Surgery 122, 1117–1123 (1997).
Wermers, R. A. et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am. J. Med. 104, 115–122 (1998).
Vestergaard, P. et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J. Surg. 27, 216–222 (2003).
Streeten, E. A. et al. Coronary artery calcification in patients with primary hyperparathyroidism in comparison with control subjects from the multi-ethnic study of atherosclerosis. Endocr. Pract. 14, 155–161 (2008).
Kepez, A. et al. Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients. Int. J. Cardiovasc. Imag. 25, 187–193 (2009).
Stefenelli, T. et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am. J. Med. 95, 197–202 (1993).
Iwata, S. et al. Aortic valve calcification in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 97, 132–137 (2012).
Walker, M. D. et al. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur. J. Endocrinol. 167, 277–285 (2012).
McMahon, D. J. et al. Effect of parathyroidectomy upon left ventricular mass in primary hyperparathyroidism: a meta-analysis. J. Clin. Endocrinol. Metab. 100, 4399–4407 (2015).
Nilsson, I. L., Aberg, J., Rastad, J. & Lind, L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 126, 1049–1055 (1999).
Kosch, M. et al. Studies on flow-mediated vasodilation and intima–media thickness of the brachial artery in patients with primary hyperparathyroidism. Am. J. Hypertens. 13, 759–764 (2000).
Lumachi, F. et al. Intima-media thickness measurement of the carotid artery in patients with primary hyperparathyroidism. A prospective case–control study and long-term follow-up. In Vivo 20, 887–890 (2006).
Fallo, F. et al. Ultrasound evaluation of carotid artery in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88, 2096–2099 (2003).
Rosa, J. et al. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens. Res. 34, 296–300 (2011).
Schillaci, G. et al. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 218, 96–101 (2011).
Rubin, M. R., Maurer, M. S., McMahon, D. J., Bilezikian, J. P. & Silverberg, S. J. Arterial stiffness in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90, 3326–3330 (2005).
Ragno, A. et al. Chronic constipation in hypercalcemic patients with primary hyperparathyroidism. Eur. Rev. Med. Pharmacol. Sci. 16, 884–889 (2012).
Pepe, J. et al. The effect of parathyroidectomy on chronic constipation in patients affected by primary hyperparathyroidism. J. Bone Miner. Metab. 31, 690–694 (2013).
Ludvigsson, J. F. et al. Primary hyperparathyroidism and celiac disease: a population-based cohort study. J. Clin. Endocrinol. Metab. 97, 897–904 (2012).
Bilezikian, J. P., Khan, A. A. & Potts, J. T. Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009).
Cusano, N. E. et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J. Clin. Endocrinol. Metab. 98, 2734–2741 (2013).
Maruani, G., Hertig, A., Paillard, M. & Houillier, P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J. Clin. Endocrinol. Metab. 88, 4641–4648 (2003).
Rejnmark, L., Amstrup, A. K., Mollerup, C. L., Heickendorff, L. & Mosekilde, L. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case–control study. J. Clin. Endocrinol. Metab. 98, 87–96 (2013).
Tuna, M. M. et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Miner. Metab. 34, 331–335 (2016).
Koumakis, E. et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 98, 3213–3220 (2013).
Abdulla, A. G., Ituarte, P. H., Harari, A., Wu, J. X. & Yeh, M. W. Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10 years. Ann. Surg. 261, 746–750 (2015).
Stavrakis, A. I., Ituarte, P. H., Ko, C. Y. & Yeh, M. W. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 142, 887–899 (2007).
Kluijfhout, W. P. et al. Fluorine-18 fluorocholine PET–CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl. Med. Commun. 37, 1246–1252 (2016).
Udelsman, R. & Donovan, P. I. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann. Surg. 244, 471–479 (2006).
Rao, D. S., Phillips, E. R., Divine, G. W. & Talpos, G. B. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 89, 5415–5422 (2004).
Rolighed, L. et al. BMD improvements after operation for primary hyperparathyroidism. Langenbecks Arch. Surg. 398, 113–120 (2013).
Mollerup, C. L. et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 325, 807 (2002).
Rubin, M. R. et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metab. 93, 3462–3470 (2008).
Zanocco, K. A., Wu, J. X. & Yeh, M. W. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery 161, 16–24 (2017).
Locker, F. G., Silverberg, S. J. & Bilezikian, J. P. Optimal dietary calcium intake in primary hyperparathyroidism. Am. J. Med. 102, 543–550 (1997).
Paik, J. M., Curhan, G. C. & Taylor, E. N. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ 345, e6390 (2012).
Marcocci, C., Bollerslev, J., Khan, A. A. & Shoback, D. M. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J. Clin. Endocrinol. Metab. 99, 3607–3618 (2014).
Jorde, R., Szumlas, K., Haug, E. & Sundsfjord, J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur. J. Nutr. 41, 258–263 (2002).
Tsvetov, G. et al. Thiazide treatment in primary hyperparathyroidism — a new indication for an old medication? J. Clin. Endocrinol. Metab. 102, 1270–1276 (2017).
Riss, P. et al. The influence of thiazide intake on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 85, 196–201 (2016).
Farquhar, C. W., Spathis, G. S., Barron, J. L. & Levin, G. E. Failure of thiazide diuretics to increase plasma calcium in mild primary hyperparathyroidism. Postgrad. Med. J. 66, 714–716 (1990).
Grey, A. B., Stapleton, J. P., Evans, M. C., Tatnell, M. A. & Reid, I. R. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann. Intern. Med. 125, 360–368 (1996).
Tournis, S. et al. Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J. Bone Miner. Metab. 32, 151–158 (2014).
Acknowledgements
The authors acknowledge the National Institiutes of Health (NIH; Grants DK074457 and DK084986 to S.J.S. and DK104105 to M.D.W.).
Author information
Authors and Affiliations
Contributions
M.D.W. and S.J.S. researched data for the article, made substantial contributions to discussions of the content, wrote the article and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Walker, M., Silverberg, S. Primary hyperparathyroidism. Nat Rev Endocrinol 14, 115–125 (2018). https://doi.org/10.1038/nrendo.2017.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.104
This article is cited by
-
Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa
BMC Endocrine Disorders (2024)
-
A novel index to predict postoperative hypocalcemia in primary hyperparathyroidism
Irish Journal of Medical Science (1971 -) (2024)
-
Metabolic bone disorders and the promise of marine osteoactive compounds
Cellular and Molecular Life Sciences (2024)
-
Sex-Stratified Predictors of Prolonged Operative Time and Hospital Admission in Outpatient Parathyroidectomy
Indian Journal of Otolaryngology and Head & Neck Surgery (2024)
-
The clinical significance of calcium/magnesium ratio in primary hyperparathyroidism: unveiling a clinical association
Hormones (2024)